Does Prenatal Tdap Vaccine Protect Infants From Pertussis?
Pertussis (whooping cough) can be especially dangerous early in life and is a recognized cause of infant death. Pertussis rates are increasing due to multiple factors, including changes in the newer vaccine formulations. This study by Baxter et al. (Pediatrics, 2017) aimed to determine if the tetanus toxoid, reduced diphtheria toxoid, acellular pertussis (Tdap) vaccine administered during pregnancy protects infants before the first dose of diphtheria, tetanus and acellular pertussis (DTaP) vaccine. The newborns were followed for a year to assess if there was any protection after receiving their recommended DTaP vaccines at the recommended ages (2,4 and 6 months).
Retrospective Cohort Study
148,981 newborns who received DTaP vaccine during their first year of life were included in the study. During the first two months of life the maternal Tdap vaccine was 91.4% effective (95% confidence interval [CI], 19.5 to 99.1). Effectiveness was 69.0% (95% CI, 43.6 to 82.9) during the first year of life. Maternal Tdap effectiveness was 87.9% (95% CI, 41.4 to 97.5) before infant vaccination with DTaP. Effectiveness of maternal Tdap was 81.4% (95% CI, 42.5 to 94.0) between doses one and two, 6.4% (95% CI, −165.1 to 66.9) between doses two and three, and 65.9% (95% CI, 4.5 to 87.8) following infant exposure to all three doses. These data show that even following infant’s DTaP vaccination, there was still protection from the maternal Tdap vaccination. These results support the current CDC recommendation to administer Tdap during pregnancy, and provide strong evidence that prenatal vaccination protects infants throughout their first year of life.
Please sign up or log in to your ObGFirst to access this Premium Content
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan